Look back at pharma news in week to July 6

By Barbara Obstoj-Cardwell. Editor

In regulatory news last week, upside was seen in US drug developer Dermira beyond US Food and Drug Administration approval of its dermatological product Qbrexza. As far as deal-making was concerned, Adamis Pharma at last finding a partner for its epinephrine injector Symjepi was seen as a major success. On the research front, attracting attention were Biogen and Eisai’s Phase II success with Alzheimer’s candidate BAN2491, with both companies shares leaping around 20%, and Gemphire’ positive Phase IIb results with its NASH candidate gemcabene. Meantime, the US Institute for Clinical and Economic Review’s (ICER) largely positive view on the pricing of new migraine drug Aimovig must have been music to the ears of Amgen and Novartis.

Dermira may provide some upside potential, even after latest FDA approval